Skip to main content
Erschienen in: CNS Drugs 6/2005

01.06.2005 | Therapy In Practice

Medication Overuse Headache in Patients with Primary Headache Disorders

Epidemiology, Management and Pathogenesis

verfasst von: Dr Andrew J. Dowson, David W. Dodick, Volker Limmroth

Erschienen in: CNS Drugs | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Medication overuse headache (MOH) is a common medical condition that is associated with considerable long-term morbidity and disability. Patients experiencing MOH have primary headache disorders (migraine, tension-type headache [TTH] or the combination of migraine and TTH) that change to a pattern of daily or near-daily headaches over a period of years or decades following the overuse of symptomatic headache medications. Overused drugs include analgesics, ergot alkaloids, serotonin 5-HT1b/1d receptor agonists (‘triptans’) and medications containing barbiturates, codeine, caffeine, tranquillisers and mixed analgesics. Affected patients usually have a long history of primary headache, overuse of medications and MOH before they consult a physician for care. Patients with MOH are usually managed in specialist centres by withdrawal of the overused drugs and treatment of withdrawal symptoms (on an inpatient or outpatient basis), headache prophylaxis and limited use of symptomatic acute medications. Most patients respond to this therapy, although the prognosis is not always good and ≥50% may lapse over an initial 5-year follow-up period. The best practical strategy at present is to prevent the overuse of drugs in the first place by patient education and formal management approaches conducted in primary care to treat the primary headache before it changes to MOH. The quality of the clinical evidence on MOH is suboptimal and further biological and clinical research is urgently required to help facilitate the management of these patients more effectively in the future.
Literatur
1.
2.
Zurück zum Zitat Dowson AJ. Your questions answered: migraine and other headaches. Edinburgh: Churchill Livingstone, 2003 Dowson AJ. Your questions answered: migraine and other headaches. Edinburgh: Churchill Livingstone, 2003
3.
Zurück zum Zitat Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004; 24 Suppl. 1: 1–160 Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004; 24 Suppl. 1: 1–160
4.
Zurück zum Zitat Peters GA, Horton BT. Headache: with special reference to excessive use of ergotamine preparations and withdrawal effects. Mayo Clin Proc 1951; 26: 214–26 Peters GA, Horton BT. Headache: with special reference to excessive use of ergotamine preparations and withdrawal effects. Mayo Clin Proc 1951; 26: 214–26
5.
Zurück zum Zitat Mathew NT. Chronic refractory headache. Neurology 1993; 43(6 Suppl. 3): 26–33 Mathew NT. Chronic refractory headache. Neurology 1993; 43(6 Suppl. 3): 26–33
6.
Zurück zum Zitat Sanin LC, Mathew NT, Bellmeyer LR, et al. The International Headache Society (IHS) headache classification as applied to a headache clinic population. Cephalalgia 1994; 14: 443–6PubMedCrossRef Sanin LC, Mathew NT, Bellmeyer LR, et al. The International Headache Society (IHS) headache classification as applied to a headache clinic population. Cephalalgia 1994; 14: 443–6PubMedCrossRef
7.
Zurück zum Zitat Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache 2003; 43: 14–8PubMedCrossRef Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache 2003; 43: 14–8PubMedCrossRef
8.
Zurück zum Zitat Mathew NT. Transformed migraine. Cephalalgia 1993; 13 Suppl. 12: 78–83 Mathew NT. Transformed migraine. Cephalalgia 1993; 13 Suppl. 12: 78–83
9.
Zurück zum Zitat Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States; relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64–9PubMedCrossRef Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States; relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64–9PubMedCrossRef
10.
Zurück zum Zitat Hagen K, Vatten L, Stovner LJ, et al. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22 718 adults in Norway. Cephalalgia 2002; 22: 672–9PubMedCrossRef Hagen K, Vatten L, Stovner LJ, et al. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22 718 adults in Norway. Cephalalgia 2002; 22: 672–9PubMedCrossRef
11.
Zurück zum Zitat Silberstein SD, Young WB. Analgesic rebound headache: how great is the problem and what can be done? Drug Saf 1995; 13: 133–44PubMedCrossRef Silberstein SD, Young WB. Analgesic rebound headache: how great is the problem and what can be done? Drug Saf 1995; 13: 133–44PubMedCrossRef
12.
Zurück zum Zitat Castillo J, Munoz P, Guitera V, et al. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190–6PubMedCrossRef Castillo J, Munoz P, Guitera V, et al. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190–6PubMedCrossRef
13.
Zurück zum Zitat Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36: 14–9PubMedCrossRef Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36: 14–9PubMedCrossRef
14.
Zurück zum Zitat Eggen AE. The Tromsø study: frequency and predicting factors of analgesic drug use in a free living population (12–56 years). J Clin Epidemiol 1993; 46: 1297–304PubMedCrossRef Eggen AE. The Tromsø study: frequency and predicting factors of analgesic drug use in a free living population (12–56 years). J Clin Epidemiol 1993; 46: 1297–304PubMedCrossRef
15.
Zurück zum Zitat Gutzwiller F, Zemp E. Der analgetikakonsum in der Bevölkerung und socioökonomische aspekte des analge-tikaabusus. In: Mihatsch MJ, editor. Das Analgetikasyndrom. Stuttgart: Thieme, 1986: 197–205 Gutzwiller F, Zemp E. Der analgetikakonsum in der Bevölkerung und socioökonomische aspekte des analge-tikaabusus. In: Mihatsch MJ, editor. Das Analgetikasyndrom. Stuttgart: Thieme, 1986: 197–205
16.
Zurück zum Zitat Schwarz A, Farber U, Glaeske G, et al. Dated zu analgetikakonsum und analgetikanephropathie in der bundesrepublik. Offen-tiches Gesundheitswesen 1985; 47: 298–300 Schwarz A, Farber U, Glaeske G, et al. Dated zu analgetikakonsum und analgetikanephropathie in der bundesrepublik. Offen-tiches Gesundheitswesen 1985; 47: 298–300
17.
Zurück zum Zitat Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample. Headache 1992; 32: 223–8PubMedCrossRef Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample. Headache 1992; 32: 223–8PubMedCrossRef
18.
Zurück zum Zitat Robinson RG. Pain relief for headaches. Can Fam Physician 1993; 39: 867–72PubMed Robinson RG. Pain relief for headaches. Can Fam Physician 1993; 39: 867–72PubMed
19.
Zurück zum Zitat Von Korff M, Galer BS, Stang P. Chronic use of symptomatic headache medications. Pain 1995; 62: 179–86CrossRef Von Korff M, Galer BS, Stang P. Chronic use of symptomatic headache medications. Pain 1995; 62: 179–86CrossRef
20.
Zurück zum Zitat Schnider P, Aull S, Feucht M, et al. Use and abuse of analgesics in tension-type headache. Cephalalgia 1994; 14: 162–7PubMedCrossRef Schnider P, Aull S, Feucht M, et al. Use and abuse of analgesics in tension-type headache. Cephalalgia 1994; 14: 162–7PubMedCrossRef
21.
Zurück zum Zitat Micieli G, Manzoni GC, Granella F, et al. Clinical and epidemiological observations on drug abuse in headache patients. In: Diener H-C, Wilkinson M, editors. Drug-induced headache. Berlin: Springer-Verlag, 1988: 20–8CrossRef Micieli G, Manzoni GC, Granella F, et al. Clinical and epidemiological observations on drug abuse in headache patients. In: Diener H-C, Wilkinson M, editors. Drug-induced headache. Berlin: Springer-Verlag, 1988: 20–8CrossRef
23.
Zurück zum Zitat Solomon S, Lipton RB, Newman LC. Clinical features of chronic daily headache. Headache 1992; 32: 325–9PubMedCrossRef Solomon S, Lipton RB, Newman LC. Clinical features of chronic daily headache. Headache 1992; 32: 325–9PubMedCrossRef
24.
Zurück zum Zitat Silberstein SD, Saper J. Migraine: diagnosis and treatment. In: Dalessio D, Silberstein SD, editors. Wolff ’s headache and other head pain. New York: Oxford University Press, 1993: 96–170 Silberstein SD, Saper J. Migraine: diagnosis and treatment. In: Dalessio D, Silberstein SD, editors. Wolff ’s headache and other head pain. New York: Oxford University Press, 1993: 96–170
25.
Zurück zum Zitat Diener H-C, Tfelt-Hansen P. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press, 1993: 721–7 Diener H-C, Tfelt-Hansen P. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press, 1993: 721–7
26.
Zurück zum Zitat Zwart J-A, Dyb G, Hagen K, et al. Analgesic use: a predictor of chronic pain and medication overuse headache. The Head-HUNT Study. Neurology 2003; 61: 160–4 Zwart J-A, Dyb G, Hagen K, et al. Analgesic use: a predictor of chronic pain and medication overuse headache. The Head-HUNT Study. Neurology 2003; 61: 160–4
27.
Zurück zum Zitat Lipton RB, Bigal ME. Chronic daily headache: is analgesic overuse a cause or a consequence? Neurology 2003; 61: 154–5PubMedCrossRef Lipton RB, Bigal ME. Chronic daily headache: is analgesic overuse a cause or a consequence? Neurology 2003; 61: 154–5PubMedCrossRef
28.
Zurück zum Zitat Limmroth V, Kazarawa S, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011–4PubMedCrossRef Limmroth V, Kazarawa S, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011–4PubMedCrossRef
30.
Zurück zum Zitat Silberstein SD, Lipton R, Solomon S, et al. Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994; 34: 1–7CrossRef Silberstein SD, Lipton R, Solomon S, et al. Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994; 34: 1–7CrossRef
31.
Zurück zum Zitat Baumgartner C, Wessely P, Bingöl C, et al. Long term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 1989; 29: 10–4CrossRef Baumgartner C, Wessely P, Bingöl C, et al. Long term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 1989; 29: 10–4CrossRef
32.
Zurück zum Zitat Diener H-C, Bühler K, Dichgans J, et al. Analgetikainduzierter Dauerkopfschmerz. Existiert eine kritische Dosis? Arzneimitteltherapie 1988; 6: 156–64 Diener H-C, Bühler K, Dichgans J, et al. Analgetikainduzierter Dauerkopfschmerz. Existiert eine kritische Dosis? Arzneimitteltherapie 1988; 6: 156–64
33.
Zurück zum Zitat Mathew NT, Kurman R, Perez F. Drug induced refractory headache: clinical features and management. Headache 1990; 30: 634–8PubMedCrossRef Mathew NT, Kurman R, Perez F. Drug induced refractory headache: clinical features and management. Headache 1990; 30: 634–8PubMedCrossRef
34.
Zurück zum Zitat Silverman K, Evans SM, Strain EC, et al. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992; 327: 1109–14PubMedCrossRef Silverman K, Evans SM, Strain EC, et al. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992; 327: 1109–14PubMedCrossRef
35.
Zurück zum Zitat Feinstein AR, Heinemann LA, Dalessio D, et al. Do caffeine-containing analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000; 68: 457–67PubMedCrossRef Feinstein AR, Heinemann LA, Dalessio D, et al. Do caffeine-containing analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000; 68: 457–67PubMedCrossRef
36.
Zurück zum Zitat Williams D, Cahill T, Dowson A, et al. Usage of triptans among migraine patients: an audit in nine GP practices. Curr Med Res Opin 2002; 18: 1–9PubMed Williams D, Cahill T, Dowson A, et al. Usage of triptans among migraine patients: an audit in nine GP practices. Curr Med Res Opin 2002; 18: 1–9PubMed
37.
Zurück zum Zitat Gaist D, Andersen M, Aarup AL, et al. Use of sumatriptan in Denmark in 1994–5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997; 43: 429–33PubMedCrossRef Gaist D, Andersen M, Aarup AL, et al. Use of sumatriptan in Denmark in 1994–5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997; 43: 429–33PubMedCrossRef
38.
Zurück zum Zitat Gaist D, Hallas J, Sindrup SH, et al. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996; 50: 161–5PubMedCrossRef Gaist D, Hallas J, Sindrup SH, et al. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996; 50: 161–5PubMedCrossRef
39.
Zurück zum Zitat Gaist D, Tsiropoulus I, Sindrup SH, et al. Inappropriate use of sumatriptan: population based register and interview study. BMJ 1998; 316: 1352–3PubMedCrossRef Gaist D, Tsiropoulus I, Sindrup SH, et al. Inappropriate use of sumatriptan: population based register and interview study. BMJ 1998; 316: 1352–3PubMedCrossRef
40.
Zurück zum Zitat Pini LA, Trenti T. Case report: does chronic use of sumatriptan induce dependence? Headache 1994; 34: 600–1PubMedCrossRef Pini LA, Trenti T. Case report: does chronic use of sumatriptan induce dependence? Headache 1994; 34: 600–1PubMedCrossRef
41.
Zurück zum Zitat Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694–8PubMedCrossRef Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694–8PubMedCrossRef
42.
Zurück zum Zitat Katsarava Z, Diener H-C, Limmroth V. Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans. Drug Saf 2001; 24: 921–7PubMedCrossRef Katsarava Z, Diener H-C, Limmroth V. Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans. Drug Saf 2001; 24: 921–7PubMedCrossRef
43.
Zurück zum Zitat Limmroth V, Kazarawa S, Fritsche G, et al. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan [letter]. Lancet 1999; 353: 378PubMedCrossRef Limmroth V, Kazarawa S, Fritsche G, et al. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan [letter]. Lancet 1999; 353: 378PubMedCrossRef
44.
Zurück zum Zitat Evers S, Gralow I, Bauer B, et al. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999; 22: 201–6PubMed Evers S, Gralow I, Bauer B, et al. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999; 22: 201–6PubMed
45.
Zurück zum Zitat Diener H-C, Katsarava Z. Medication overuse headache. Curr Med Res Opin 2001; 17 Suppl. 1: 17–21CrossRef Diener H-C, Katsarava Z. Medication overuse headache. Curr Med Res Opin 2001; 17 Suppl. 1: 17–21CrossRef
46.
Zurück zum Zitat Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754–762PubMedCrossRef Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754–762PubMedCrossRef
47.
Zurück zum Zitat Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002; 18: 414–39PubMedCrossRef Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002; 18: 414–39PubMedCrossRef
48.
Zurück zum Zitat Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999; 33: 61–72PubMedCrossRef Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999; 33: 61–72PubMedCrossRef
49.
Zurück zum Zitat Diener H-C, Dahlöf CGH. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 1999: 871–8 Diener H-C, Dahlöf CGH. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 1999: 871–8
50.
Zurück zum Zitat Haag G, Baar H, Grotemeyer KH, et al. Prophylaxe und Therapie des medikamenteninduzierten Dauerkopfschmerzes. Schmerz 1999; 13: 52–7PubMedCrossRef Haag G, Baar H, Grotemeyer KH, et al. Prophylaxe und Therapie des medikamenteninduzierten Dauerkopfschmerzes. Schmerz 1999; 13: 52–7PubMedCrossRef
51.
Zurück zum Zitat Hering-Hanit R, Cohen A, Horev Z. Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. J Child Neurol 2001; 16: 448–9PubMed Hering-Hanit R, Cohen A, Horev Z. Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. J Child Neurol 2001; 16: 448–9PubMed
53.
Zurück zum Zitat Panconesi A, Del Bianco PL, Curradi C, et al. Headache caused by analgesic and/or ergotamine abuse [in Italian]. Clin Ter 1991; 137: 169–83PubMed Panconesi A, Del Bianco PL, Curradi C, et al. Headache caused by analgesic and/or ergotamine abuse [in Italian]. Clin Ter 1991; 137: 169–83PubMed
54.
Zurück zum Zitat Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000; 20: 107–13PubMedCrossRef Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000; 20: 107–13PubMedCrossRef
55.
Zurück zum Zitat Diener H-C, Haab J, Peters C, et al. Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache 1990; 31: 205–9CrossRef Diener H-C, Haab J, Peters C, et al. Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache 1990; 31: 205–9CrossRef
56.
57.
Zurück zum Zitat Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003; 23: 963–71PubMedCrossRef Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003; 23: 963–71PubMedCrossRef
58.
Zurück zum Zitat Diener H-C, Dichgans J, Scholz E, et al. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989; 236: 9–14PubMedCrossRef Diener H-C, Dichgans J, Scholz E, et al. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989; 236: 9–14PubMedCrossRef
59.
Zurück zum Zitat Descombes S, Brefel-Courbon C, Thalamas C, et al. Amitriptyline treatment in chronic drug-induced headache: a double-blind comparative pilot study. Headache 2001; 41: 178–82PubMedCrossRef Descombes S, Brefel-Courbon C, Thalamas C, et al. Amitriptyline treatment in chronic drug-induced headache: a double-blind comparative pilot study. Headache 2001; 41: 178–82PubMedCrossRef
60.
Zurück zum Zitat Jevoux CC, Moreira Filho PF, de Souza JA. Primary chronic daily headache: a report on 52 cases [in Portuguese]. Arq Neuropsiquiatr 1998; 56: 69–77 Jevoux CC, Moreira Filho PF, de Souza JA. Primary chronic daily headache: a report on 52 cases [in Portuguese]. Arq Neuropsiquiatr 1998; 56: 69–77
61.
Zurück zum Zitat Bonuccelli U, Nuti A, Lucetti C, et al. Amitriptyline and dexamethasone combined treatment in drug-induced headache. Cephalalgia 1996; 16: 198–200PubMedCrossRef Bonuccelli U, Nuti A, Lucetti C, et al. Amitriptyline and dexamethasone combined treatment in drug-induced headache. Cephalalgia 1996; 16: 198–200PubMedCrossRef
62.
Zurück zum Zitat Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache: an open labelled study. Headache 1991; 31: 71–4PubMedCrossRef Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache: an open labelled study. Headache 1991; 31: 71–4PubMedCrossRef
63.
Zurück zum Zitat Smith TR. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache 2002; 42: 175–7PubMedCrossRef Smith TR. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache 2002; 42: 175–7PubMedCrossRef
64.
Zurück zum Zitat Tribl GG, Schnider P, Wöber C, et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache? Cephalalgia 2001; 21: 691–6PubMedCrossRef Tribl GG, Schnider P, Wöber C, et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache? Cephalalgia 2001; 21: 691–6PubMedCrossRef
65.
Zurück zum Zitat Fritsche G, Eberl A, Katsarava Z, et al. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001; 45: 229–35PubMedCrossRef Fritsche G, Eberl A, Katsarava Z, et al. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001; 45: 229–35PubMedCrossRef
66.
Zurück zum Zitat Pini L-A, Cicero AFG, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 2001; 21: 878–83PubMedCrossRef Pini L-A, Cicero AFG, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 2001; 21: 878–83PubMedCrossRef
67.
Zurück zum Zitat Katsarava Z, Limmroth V, Finke M, et al. Rate and predictors for relapse in medication overuse headache: a one year prospective study. Neurology 2003; 60: 182–3CrossRef Katsarava Z, Limmroth V, Finke M, et al. Rate and predictors for relapse in medication overuse headache: a one year prospective study. Neurology 2003; 60: 182–3CrossRef
68.
Zurück zum Zitat Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study, Cephalagia 2005; 25: 12–15 Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study, Cephalagia 2005; 25: 12–15
69.
Zurück zum Zitat Barone-Kaganas I. Drug-induced headache and its treatment. Schweiz Med Wochenschr 1999; 129: 446–9PubMed Barone-Kaganas I. Drug-induced headache and its treatment. Schweiz Med Wochenschr 1999; 129: 446–9PubMed
70.
Zurück zum Zitat Burstein R, Yarnitsky D, Good-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614–24PubMedCrossRef Burstein R, Yarnitsky D, Good-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614–24PubMedCrossRef
71.
Zurück zum Zitat Burstein R, Cutrer M, Yarnitzky D. The development of cutaneous allodynia during migraine attacks: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: 1703–9PubMedCrossRef Burstein R, Cutrer M, Yarnitzky D. The development of cutaneous allodynia during migraine attacks: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: 1703–9PubMedCrossRef
72.
Zurück zum Zitat Welch KMA, Nagesh V, Aurora SK, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001; 41: 629–37PubMedCrossRef Welch KMA, Nagesh V, Aurora SK, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001; 41: 629–37PubMedCrossRef
73.
Zurück zum Zitat Srikiatkhachorn A. Chronic daily headache: a scientist’s perspective. Headache 2002; 42: 532–7PubMedCrossRef Srikiatkhachorn A. Chronic daily headache: a scientist’s perspective. Headache 2002; 42: 532–7PubMedCrossRef
74.
Zurück zum Zitat Ekbom K, Krabbe A, Micieli G, et al. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Cephalalgia 1995; 15: 230–6PubMedCrossRef Ekbom K, Krabbe A, Micieli G, et al. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Cephalalgia 1995; 15: 230–6PubMedCrossRef
75.
Zurück zum Zitat Bahra A, Walsh M, Menon S, et al. Does chronic daily headache arise de novo in association with regular analgesic use? Headache 2003; 43: 179–90PubMedCrossRef Bahra A, Walsh M, Menon S, et al. Does chronic daily headache arise de novo in association with regular analgesic use? Headache 2003; 43: 179–90PubMedCrossRef
76.
Zurück zum Zitat Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous migraine attacks. Nat Med 1995; 1: 658–60PubMedCrossRef Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous migraine attacks. Nat Med 1995; 1: 658–60PubMedCrossRef
77.
Zurück zum Zitat Saucier C, Morris SJ, Albert PR. Endogenous serotonin-2A and-2C receptors in Balb/c-3T3 cells revealed in serotonin-free medium: desensitization and down-regulation by serotonin. Biochem Pharmacol 1998; 56: 1347–57PubMedCrossRef Saucier C, Morris SJ, Albert PR. Endogenous serotonin-2A and-2C receptors in Balb/c-3T3 cells revealed in serotonin-free medium: desensitization and down-regulation by serotonin. Biochem Pharmacol 1998; 56: 1347–57PubMedCrossRef
78.
Zurück zum Zitat Cox BM. Drug tolerance and physical dependence. In: Pratt WB, Taylor P, editors. Principles of drug action: the basis of pharmacology. Churchill Livingstone: New York, 1990: 639–90 Cox BM. Drug tolerance and physical dependence. In: Pratt WB, Taylor P, editors. Principles of drug action: the basis of pharmacology. Churchill Livingstone: New York, 1990: 639–90
79.
80.
Zurück zum Zitat Foley KM. Misconceptions and controversies regarding the use of opioids in cancer pain. Anticancer Drugs 1995; 6 Suppl. 3: 4–13CrossRef Foley KM. Misconceptions and controversies regarding the use of opioids in cancer pain. Anticancer Drugs 1995; 6 Suppl. 3: 4–13CrossRef
81.
Zurück zum Zitat Arner S, Rawal N, Gustafsson LL. Clinical experience of long-term treatment with epidural and intrathecal opioids: a nationwide survey. Acta Anaesthesiol Scand 1988; 32: 253–9PubMedCrossRef Arner S, Rawal N, Gustafsson LL. Clinical experience of long-term treatment with epidural and intrathecal opioids: a nationwide survey. Acta Anaesthesiol Scand 1988; 32: 253–9PubMedCrossRef
82.
Zurück zum Zitat Devulder J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol 1997; 9: 146–8PubMedCrossRef Devulder J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol 1997; 9: 146–8PubMedCrossRef
83.
Zurück zum Zitat Eisenach JC. Preemptive hyperalgesia, not analgesia? Anesthe-siology 2000; 92: 308–9CrossRef Eisenach JC. Preemptive hyperalgesia, not analgesia? Anesthe-siology 2000; 92: 308–9CrossRef
84.
Zurück zum Zitat Yaksh TL, Kohl RL, Rudy TA. Induction of tolerance and withdrawal in rats receiving morphine in the spinal subarach-noid space. Eur J Pharmacol 1977; 42: 275–84PubMedCrossRef Yaksh TL, Kohl RL, Rudy TA. Induction of tolerance and withdrawal in rats receiving morphine in the spinal subarach-noid space. Eur J Pharmacol 1977; 42: 275–84PubMedCrossRef
85.
Zurück zum Zitat Yaksh TL, Harty GJ, Onofrio BM. High doses of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology 1986; 64: 590–7PubMedCrossRef Yaksh TL, Harty GJ, Onofrio BM. High doses of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology 1986; 64: 590–7PubMedCrossRef
86.
Zurück zum Zitat Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther 1988; 244: 501–7PubMed Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther 1988; 244: 501–7PubMed
87.
Zurück zum Zitat Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995; 62: 259–74PubMedCrossRef Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995; 62: 259–74PubMedCrossRef
88.
Zurück zum Zitat Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20: 7074–9PubMed Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20: 7074–9PubMed
89.
Zurück zum Zitat Vanderah TW, Suenaga NMH, Ossipov MH, et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 2001; 21: 279–86PubMed Vanderah TW, Suenaga NMH, Ossipov MH, et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 2001; 21: 279–86PubMed
90.
Zurück zum Zitat Claude P, Gracia N, Wagner L, et al. Effect of dynorphin on ICGRP release from capsaicin-sensitive fibers.Abstracts of the Ninth World Congress on Pain; Vienna 1999 Claude P, Gracia N, Wagner L, et al. Effect of dynorphin on ICGRP release from capsaicin-sensitive fibers.Abstracts of the Ninth World Congress on Pain; Vienna 1999
91.
Zurück zum Zitat Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ 1997; 156: 1273-87PubMed Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ 1997; 156: 1273-87PubMed
Metadaten
Titel
Medication Overuse Headache in Patients with Primary Headache Disorders
Epidemiology, Management and Pathogenesis
verfasst von
Dr Andrew J. Dowson
David W. Dodick
Volker Limmroth
Publikationsdatum
01.06.2005
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 6/2005
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200519060-00002

Weitere Artikel der Ausgabe 6/2005

CNS Drugs 6/2005 Zur Ausgabe

Therapy In Practice

Migraine During Pregnancy

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.